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Abstract
Objectives: To investigate whether normal variation of adult height is associated with clinical characteristics in rheumatoid
arthritis (RA), including disease activity (DAS28), impairment of joint function (mechanical joint score, MJS) and overall
disability (health assessment questionnaire, HAQ).
Methods: A cohort (134 males, 287 females) of consecutively recruited RA patients of Northern European origin was studied.
Height, weight and demographic information were obtained. A core set of disease measurements, including DAS28, MJS
and HAQ, were recorded at baseline, 12 and 24 months. Other clinical variables (e.g. disease duration, IgM rheumatoid
factor, antibodies to cyclic citrullinated peptide, C-reactive protein, erythrocyte sedimentation rate) were recorded at
baseline. Socioeconomic status, smoking status, comorbid condition, other autoimmune conditions and drug therapy were
also recorded. Associations were analyzed using univariate statistics and multivariate linear regression models. Mediation
tests were also carried out for evaluating the relationship between gender, height and disease measures.
Results: In males, height was inversely associated with DAS28, MJS and HAQ (at baseline and over 24 months) independent
of other factors (e.g. weight, body mass index, age, disease duration, osteoporosis, autoantibodies, erosive disease, joint
replacement, steroid use, smoking status, socioeconomic status and comorbid disease). In females, a similar trend was seen
but the relationships were non significant. In the whole population, the association of female gender with more active
disease and poor function disappeared after adjustment for height. Mediation analysis indicated that height served as a full
mediator in the relationship of gender with disease activity and overall disability. Confirmation of these findings was
demonstrated in a second RA population (n = 288).
Conclusion: Adult height is inversely associated with disease activity, impairment of joint function and overall disability in
RA, particularly in males. The association of female sex with more severe disease activity and disability appears to be
mediated by smaller stature.
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Introduction
Body height is among the most visible of human characteristics,
and is highly heritable (h2 = 0.8) [1]. It has been associated with
numerous genomic loci (n.100), with each contributing a small
amount of effect [2]. It is a complex trait also influenced by a
variety of environmental factors, including diet and the prenatal
environment [3].
Normal variation of height in adulthood is associated with
several disease conditions, including various cancers (short stature/
decreased risk) [4,5], cardiovascular diseases (CVD) (short stature/
increased risk) [6], type 2 diabetes (short stature/increased risk)
[7], periodontitis (short stature/increased risk) [8], and chronic
obstructive pulmonary disease (short stature/increased risk) [9].
Previous studies have found no relationship between height and
the risk of developing rheumatoid arthritis (RA) [10,11], but as far
as we are aware there have been no studies on whether there is a
relationship between height and disease activity or severity in
rheumatoid arthritis (RA).
It has been suggested that the association of short stature with
CVD and other diseases may be related to an increased
inflammatory burden in such individuals due to early-life
infections which have impact on eventual adult height [12]. We
hypothesized that there may be an association between adult
height and disease activity and/or severity in patients with RA. In
the present study we investigated whether there was a relationship
between height and a number of major disease characteristics in
RA, including disease activity, impairment of mechanical joint
function and global degree of disability. Our results suggest that, in
men particularly, height is inversely associated with increased
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disease activity, and overall severity in RA. The well described
association of female sex with more severe disease activity and
poor functional outcome appears to be mediated by smaller
stature.
Methods
Patients
This study was based on a cohort (n = 430) of consecutively
recruited RA patients of Northern European origin, resident in
North Staffordshire and attending the Clinical Rheumatology
Unit at the Haywood Hospital. All patients had a diagnosis of RA,
and met the 1987 American College of Rheumatology criteria
[13]. Nine (2.1%) samples were excluded from the current report,
on the basis that information on height, sex or any key outcome
variable was incomplete. Inclusion or exclusion of these samples
made no difference to the associations found.
Body height (standing height) and weight were measured on
each patient at baseline. Height (in cm to the nearest 0.1 cm) was
measured with a stadiometer with a measuring slide and a heel
plate. Position of the head was standardized by asking the sampled
subject to stand straight, without shoes and with the heels together.
Weight (in kg to the nearest 0.1 kg) was measured with a reliable
weighing scale while the participant was wearing light clothing and
no shoes. Body mass index (BMI) was obtained by weight (in kg)/
height2 (in m). Five of the 421 patients were wheelchair users, but
with support it was possible for them to stand straight enough for
height measurements. All of these patients were women. Other
demographic data (e.g. age, gender, post code of residence,
occupation) was also recorded at recruitment. Socioeconomic
status was estimated by the Carstairs index of deprivation based on
postcode address [14]. A history of current or past cigarette
smoking was obtained from a questionnaire completed by each
patient at baseline, as described previously [15].
Clinical variables, including disease duration, disease activity,
IgM rheumatoid factor (RF), anti-cyclic citrullinated peptide
antibody (anti-CCP), levels of C-reactive protein (CRP) and
erythrocyte sedimentation rate (ESR), presence of extra-articular
disease (e.g. nodules, vasculitis, interstitial lung disease), and
presence of erosive disease were obtained at baseline. RA disease
activity was measured by the Disease Activity Score 28 (DAS28).
Evaluation of DAS28 includes the number of swollen and tender
joints (based on 28 joints), the global visual analogue scale, and
ESR [16]. The Mechanical Joint Score (MJS) and the Health
Assessment Questionnaire (HAQ) score were used to assess the
total amount of joint impairment of mechanical function and the
overall degree of disability, respectively [17,18]. These three
outcome variables were obtained at baseline, 12 and 24 months
follow-up. Complete data at all time points over 24 months was
available on 305/430 (72.4%) patients.
Patients were also categorized into those with or without
osteoporosis at the time of study entry. Patients were classified has
having osteoporosis if their T scores obtained by bone densitom-
etry were less than 22.5, and/or if they were being treated with
anti-osteoporotic drugs. Previous/current medication and any
major comorbid conditions (e.g. ischaemic heart disease (IHD),
diabetes, chronic pulmonary disease, renal disease, neoplasia) on
each patient were recorded at recruitment, as described previously
[15]. Other variables recorded included evidence of other
autoimmune conditions (e.g. Sjogren’s syndrome, autoimmune
thyroid disease, inflammatory bowel disease), any hypothyroidism,
and any history of knee or hip joint replacement.
A second study population of patients (n = 288, median age
62.0, median disease duration 8.0 years, female n = 175) was used
in a replication study of the association of height with clinical
characteristics. DAS28 scores were obtained on the majority of
patients (n = 285), although HAQ scores were only available for 94
patients. MJS data were not collected. This group was on standard
disease modifying anti-rheumatic drug (DMARD) therapy and
had been recruited as a control group for patients on biologic
therapy in previous studies.
Ethics statement
Written informed consent was provided by each patient
according to the Declaration of Helsinki. The research was
approved by the North Staffordshire Local Research Ethics
Committee.
Statistical analysis
The relationship between binary variables was assessed using
contingency tables. The relationship between binary variables and
quantitative variable was assessed using two-sample T-test
(Student’s, Aspin-Welch or Mann-Whitney U Test, according to
the distribution and the variance). Correlation testing (Pearson’s or
Spearman’s Correlation, according to the distribution) was used to
assess the relationship between quantitative variables. Multivariate
linear modelling (multivariate multiple regression) was used to
assess the influence of independent variable (e.g. body height, sex)
on dependent variable (e.g. disease activity) with or without
adjustment for other covariates. The selection of other covariates
in each model was based on an all possible regressions procedure
to determine which candidate variables should be included in the
final model. This algorithm seeks a subset that provides a
maximum value of R-squared. Multiple regression analyses were
then run to determine the regression coefficients and p values for
each of the independent variables chosen in the final model. Each
regression analysis was examined for multicollinearity by looking
at the variance inflation factors, tolerances and condition number
test. The mediation effect was assessed by using the Preacher and
Hayes’ method for assessing and comparing indirect effects in
mediator models [19]. The macro for this method, called
INDIRECT, can be accessed at http://www.afhayes.com/spss-
sas-and-mplus-macros-and-code.html. This macro estimates the
path coefficients and generates bootstrap confidence intervals for
indirect effects through mediator variables, and allows for
adjustment for other covariates. Analyses were all carried out
using the Number Cruncher Statistical System for Windows
(version NCSS 2007), except for the mediation tests (SPSS version
20 with the INDIRECT macro). The significance level was set at a
p value of 0.05, and all p values were based on 2-tailed tests. MJS
did not fit a normal distribution and was square root transformed
in multiple regression models to fit normality.
Results
Characteristics of patients
The cohort consisted of 134 (31.8%) male and 287 female
patients with RA. Table 1 shows the demographic and clinical
variables at baseline. In this particular population, female patients
were younger, and a significantly higher percentage of female
patients were currently receiving methotrexate. As expected,
females were shorter with lower body weight. There was no
difference in BMI between genders. Ever-smoking was less
frequent in females than males. Female patients with RA were
associated with earlier onset, higher DAS28 (non-significant),
higher HAQ score, and a greater frequency of osteoporosis and
hypothyroidism. Males were more likely to be associated with
common co-morbid conditions (e.g. hypertension, IHD, diabetes).
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These remained significantly associated after adjustment for age
and disease duration.
Body height and RA in sex-separated analysis
Body height in males ranged between 157 and 197 cm, and in
females between 146 and 180.5 cm. Table 2 shows the selected
characteristics compared between patients below (,), and equal or
above ($) median height for male (173.3 cm) and female patients
(160.5 cm) separately.
It was a prerequisite of the present study to avoid the
confounding effect of age on body height and on other parameters
e.g. the younger generation tends to be taller, and increasing age
may be associated with reduction in height. The correlations
between height (continuous variable) and age in males and females
were (r =20.22, p = 0.010) and (r =20.15, p = 0.014), respective-
ly. All analyses were therefore adjusted for age.
Association with disease activity and outcome indices
In males, patients ,median height were associated with higher
DAS28, MJS (borderline association) and HAQ score, compared
to those $median height (Table 2). The correlations of height
(continuous variable) with DAS28, MJS and HAQ score were
(r =20.25, p = 0.0039), (r =20.22, p = 0.0095) and (r =20.23,
p = 0.0066), respectively. In females, the association of ,median
height with worse RA outcome (DAS28, MJS and HAQ score)
was not significant, but showed a similar trend to that in males
Table 1. Demographic and clinical characteristics compared between female and male patients.
Parameter All patients, n = 421 Male, n =134 Female, n =287 p value"
Demographic variable
Age, yrs 62.0 (54.0–69.0) 64.5 (57.8–72.0) 60.0 (54.0–67.0) 0.0002
Body weight, kg 76.2615.3 84.2613.6 72.4614.6 ,0.0001
Height, cm 165.369.0 174.266.5 161.166.6 ,0.0001
BMI, kg/m2 27.865.1 27.864.4 27.965.5 .0.10
Ever-smoking 275/418 (65.8) 109/133 (82.0) 166/285 (58.2) ,0.0001
Carstairs score 1.10 (21.63–3.0) 1.30 (22.55–3.25) 1.10 (21.50–3.0) .0.10
RA clinical variable
Age at onset, yrs 49.6613.1 51.8612.6 48.5613.2 0.016
Duration, yrs 9.0 (3.0–17.3) 8.5 (4.0–18.3) 9.0 (2.7–17.0) .0.10
RF status 238/419 (56.8) 75/133 (56.4) 163/286 (57.0) .0.10
Anti-CCP status 308/408 (75.5) 96/130 (73.8) 212/278 (76.3) .0.10
CRP, mg/l 11.0 (4.5–20.0) 11.8 (5.0–22.9) 10.3 (4.0–19.0) .0.10
ESR, mm/hrs{ 20.0 (10.0–35.8) 16.0 (7.5–37.0) 22.0 (11.0–35.0) 0.067
PGA{ 43.0 (21.0–57.0) 46.0 (22.0–62.5) 39.5 (20.8–54.0) .0.10
TJC{ 4 (1–9) 3 (1–8) 4 (1–9) .0.10
SJC{ 3 (1–6) 2 (0–5) 3 (1–7) .0.10
DAS28 4.2061.38 4.0561.48 4.2761.33 .0.10
MJS 7.0 (3.0–15.0) 7.0 (3.0–14.0) 7.0 (3.0–16.0) .0.10
HAQ score 1.625 (1.0–2.0) 1.50 (0.875–2.0) 1.625 (1.125–2.125) 0.046
Osteoporosis 59/421 (14.0) 12/134 (9.0) 47/287 (16.4) 0.041
Joint replacement* 66/419 (15.8) 24/133 (18.0) 42/286 (14.7) .0.10
Drug treatment for RA
DMARD use 392/421 (93.1) 122/134 (91.0) 270/287 (94.1) .0.10
Methotrexate use 255/421 (60.6) 71/134 (53.0) 184/287 (64.1) 0.030
Steroid use 41/420 (9.8) 15/134 (11.2) 26/286 (9.1) .0.10
Biologic agent use 60/421 (14.3) 19/134 (14.2) 41/287 (14.3) .0.10
Co-morbid condition
Hypertension 166/418 (39.7) 66/134 (49.3) 100/284 (35.2) 0.0062
IHD 84/420 (20.0) 43/133 (32.3) 41/287 (14.3) ,0.0001
Diabetes` 32/420 (7.6) 17/133 (12.8) 15/287 (5.2) 0.0066
Hypothyroidism 27/420 (6.4) 1/133 (0.75) 26/287 (9.05) 0.001
Asthma 44/419 (10.5) 13/133 (9.8) 31/286 (10.8) .0.10
Values are n (%), mean 6 standard deviation (SD) or median (interquartile range (IQR)).
"Comparison between male and female patients, un-adjusted;
*hip or knee replacement;
{components of DAS28;
`types I and II combined.
doi:10.1371/journal.pone.0064862.t001
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(Table 2). Correlation analysis indicated that height (continuous
variable) was significantly correlated with HAQ score (r =20.14,
p = 0.017) but not with DAS28 or MJS.
To determine whether demographic, clinical and other
variables were likely to be potential confounders or effect modifiers
of the associations with height we carried out univariate linear
regression analyses to determine which variables were most
significantly associated with disease activity/severity measures.
Variables with a p value of 0.2 or less were chosen for inclusion in
further multivariate analyses. An all possible regressions procedure
was run for each disease measure to determine which subset of
candidate variables should be run in the final multiple regression
models. Introduction of weight, BMI or other variables into these
multivariate models made little or no difference to the association
with height in men, although a number of other variables were
also significant in these models. Notably, the presence of any co-
morbid disease was significantly associated with DAS28 and
HAQ, while the use of steroids was independently associated with
HAQ and MJS. The presence of RF was associated only with
DAS28, CRP was associated only with MJS, and the Carstairs
index was associated only with the HAQ. (Table 3).
In females, height was not significantly associated with any of
the disease activity/severity parameters in multivariate models
which included other significant variables (Table 4). Other
anthropometric measurements (weight or BMI) were not signifi-
cantly associated. As in men, co-morbid disease and presence of
RF was associated with DAS28, although steroid use was also
associated in women. The strongest associations with MJS were
disease duration, presence of RF and osteoporosis, while the HAQ
was associated with disease duration, ESR, Carstairs index, steroid
use and hip replacement.
The relationships between height and the mean-time-averaged
DAS28, MJS and HAQ score over 24 months (MTA-DAS28,
MJS, and HAQ score at baseline, 12 and 24 months) were also
analyzed on 103 (76.9%) male and 202 (70.4%) female patients
using similar regression models. Height showed very significant
Table 2. Demographic and clinical characteristics compared between patients with below (,) and equal or above ($) median
height in sex-separated setting.
Parameter Male patients, n = 134 Female patients, n = 287
,median, n =67 $median, n =67 p value" ,median, n =143 $median, n =144 p value"
Age, yrs 65.0 (59.0–72.0) 64.0 (52.0–72.0) .0.10 62.0 (54.0–69.0) 59.0 (53.3–66.0) .0.10
Body weight, kg 80.8612.7 87.6613.7 0.0034 68.8613.5 75.9614.8 ,0.0001
BMI, kg/m2 28.364.6 27.364.2 .0.10 28.365.5 27.465.4 .0.10
Ever smoke 53/67 (79.1) 56/66 (84.8) .0.10 85/142 (59.9) 81/143 (56.6) .0.10
Carstairs score 1.30 (21.40–3.40) 1.15 (22.73–2.88) .0.10 1.20 (21.60–3.10) 1.10 (21.40–3.0) .0.10
Duration, yrs 7.0 (4.0–14.0) 11.0 (5.0–21.0) 0.019 11.0 (3.0–18.0) 9.0 (2.50–17.0) .0.10
RF status 36/66 (54.5) 39/67 (58.2) .0.10 85/143 (59.4) 78/143 (54.5) .0.10
Anti-CCP status 48/65 (73.8) 48/75 (73.8) .0.10 112/138 (81.2) 100/140 (71.4) 0.057
CRP, mg/l 12.3 (5.0–31.2) 11.0 (4.8–20.0) .0.10 10.0 (4.3–19.0) 11.0 (4.0–19.0) .0.10
ESR, mm/hrs{ 16.0 (9.0–44.3) 15.0 (6.0–28.0) 0.071 22.0 (12.0–38.0) 19.5 (11.0–34.0) .0.10
PGA{ 46.0 (33.0–60.0) 46.0 (16.8–65.5) .0.10 43.0 (23.0–54.0) 36.0 (19.0–54.0) .0.10
TJC{ 3 (2–8) 3 (0–7) .0.10 5 (1–10) 4 (1–8) .0.10
SJC{ 2 (1–6) 2 (0–5) .0.10 3 (1–6) 3 (1–7) .0.10
DAS28 4.3461.31 3.7561.59 0.023 4.3461.37 4.2061.29 .0.10
MJS 9.0 (3.0–17.0) 6.0 (2.8–12.0) 0.076 8.0 (3.0–17.0) 6.0 (3.0–15.0) .0.10
HAQ score 1.75 (1.25–2.125) 1.25 (0.625–1.875) 0.0046 1.75 (1.25–2.125) 1.625 (1.0–2.0) .0.10
Osteoporosis 10/67 (14.9) 2/67 (3.0) 0.016 28/143 (19.6) 19/143 (13.2) .0.10
Joint replacement* 13/67 (19.4) 11/66 (16.7) .0.10 20/142 (14.1) 22/142 (15.3) .0.10
DMARD use 60/67 (89.6) 62/67 (92.5) .0.10 136/143 (95.1) 134/144 (93.1) .0.10
Methotrexate use 38/67 (56.7) 33/67 (49.3) .0.10 86/143 (60.1) 98/144 (68.1) .0.10
Steroid use 6/67 (9.0) 9/67 (13.4) .0.10 14/143 (9.8) 12/143 (8.4) .0.10
Biologic agent use 12/67 (17.9) 7/67 (10.4) .0.10 20/143 (14.0) 21/144 (14.6) .0.10
Hypertension 34/67 (50.7) 32/67 (47.8) .0.10 57/141 (40.4) 43/143 (30.1) 0.068
IHD 20/67 (29.9) 23/66 (34.8) .0.10 25/143 (17.5) 16/144 (11.1) .0.10
Diabetes` 7/67 (10.4) 10/66 (15.2) .0.10 10/143 (7.0) 5/144 (3.5) .0.10
Hypothyroidism 1/67 (1.5) 0/66 (0.0) .0.10 13/143 (9.1) 13/144 (9.0) .0.10
Asthma 7/67 (10.4) 6/66 (9.1) .0.10 21/142 (14.8) 10/144 (6.9) 0.033
Values are n (%), mean 6 SD or median (IQR).
"Comparison within gender, un-adjusted;
*hip or knee replacement;
{components of DAS28;
`types I and II combined.
doi:10.1371/journal.pone.0064862.t002
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associations with MTA-DAS28, MTA-MJS and MTA-HAQ score
in males after adjusting for other significant independent variables
(Table 5). In females there were no associations between height
and mean time-averaged disease measures in models containing
the most significant baseline variables associated with each
measure (Table 6). BMI was significantly associated with the
MTA-DAS28 in a model which also included RF and comorbid
disease.
Gender vs. height in association with disease activity and
outcome indices
Comparison between genders showed that female patients
tended to have higher scores for the DAS28 and HAQ score,
although the DAS28 association was not significant in univariate
analysis (Table 1). We hypothesized that the association of females
with more severe RA may be related to females having a generally
shorter stature than males.
In multivariate multiple regression models of the whole
population, female sex was associated with higher DAS28 and
HAQ scores after adjusting for other variables, but excluding
height (Table S1). However, after inclusion of height (continuous
variable) as a covariate in these models, the association of female
sex with higher DAS28 and HAQ score totally disappeared
(Table 7). The association of height with disease activity/severity
measures was significant in all models with or without adjustment
for gender, although the significance levels for the DAS28 and
HAQ associations were attenuated after adjusting for gender
(Table 7). Height also showed significant associations with MTA-
DAS28, MTA-MJS and MTA-HAQ score over 24 months after
adjusting for other confounding factors (Table S2).
We postulated that height may be acting as a mediator in the
relationship of gender, with disease activity and outcome indices
(Figure 1). To formally investigate this, we applied Preacher and
Hayes’ method for assessing and comparing indirect effects in
mediator models using the INDIRECT macro. The results
demonstrated that although the total effect of gender on DAS28
and HAQ was significant (c path, models 1 and 3 respectively,
Table 8), the direct effect contributed little or nothing to this (c’
path, models 1 and 3 respectively, Table 8). The indirect effect
through the mediator (i.e. height) played the major role, based on
the significance of both a and b paths, and the quantified a6b
effect (a, b, a6b paths, models 1 and 3 respectively, Table 8).
Gender did not have a significantly effect on MJS (c path, model 2,
Table 8). However, the effect of height on MJS was significant (b
path, model 2, Table 8). The analyses were adjusted for age and
disease duration, and further adjustment made no significant
difference to the results (data not shown). Similar results were also
obtained on index records over 24 months (Table S3).
To investigate whether sex influenced disease measurements in
patients with equal height, we examined a subgroup of 54 females
with height between 161.4 and 180.5 cm and a randomly selected
group of 54 height matched males with height between 161.4 and
180.5 cm. This was the maximum number of patients that could
be examined in order to achieve two groups with an equal median
height and interquartile range (median 170 cm, IQR 167–173).
Patients with osteoporosis were excluded from the analysis in order
to prevent a disproportionate number of shorter men suffering
from osteoporosis being matched for height with women.
Multivariate, multiple regression analysis showed that gender
was not associated with any disease measurement in any of the
models tested (Table 9). In contrast, in subgroups of men (n = 50)
and women (n = 50) with disparate height, containing males
between 176 and 197 cm (median 180 cm), and females between
146 and 156.8 cm (median 153 cm), female sex was associated
T
a
b
le
5
.
M
u
lt
iv
ar
ia
te
m
u
lt
ip
le
re
g
re
ss
io
n
an
al
ys
e
s
sh
o
w
in
g
b
as
e
lin
e
va
ri
ab
le
s
m
o
st
st
ro
n
g
ly
as
so
ci
at
e
d
w
it
h
D
A
S2
8
,
M
JS
an
d
H
A
Q
sc
o
re
o
ve
r
ti
m
e
(2
4
m
o
n
th
s)
in
m
al
e
p
at
ie
n
ts
w
it
h
R
A
.
M
o
d
e
l
1
,
d
e
p
e
n
d
e
n
t
v
a
ri
a
b
le
:
M
T
A
-D
A
S
2
8
M
o
d
e
l
2
,
d
e
p
e
n
d
e
n
t
v
a
ri
a
b
le
:
M
T
A
-M
JS
*
M
o
d
e
l
3
,
d
e
p
e
n
d
e
n
t
v
a
ri
a
b
le
:
M
T
A
-H
A
Q
In
d
e
p
e
n
d
e
n
t
v
a
ri
a
b
le
R
e
g
re
ss
io
n
co
e
ff
ic
ie
n
t
(S
E
)
p
v
a
lu
e
In
d
e
p
e
n
d
e
n
t
v
a
ri
a
b
le
R
e
g
re
ss
io
n
co
e
ff
ic
ie
n
t
(S
E
)
p
v
a
lu
e
In
d
e
p
e
n
d
e
n
t
v
a
ri
a
b
le
R
e
g
re
ss
io
n
co
e
ff
ic
ie
n
t
(S
E
)
p
v
a
lu
e
H
e
ig
h
t,
cm
2
0
.0
6
3
(0
.0
1
8
)
0
.0
0
0
5
H
e
ig
h
t,
cm
2
0
.0
5
5
(0
.0
1
7
)
0
.0
0
1
8
H
e
ig
h
t,
cm
2
0
.0
3
1
(0
.0
0
9
)
0
.0
0
1
6
C
o
m
o
rb
id
d
is
e
as
e
{
1
.4
7
0
(0
.4
3
4
)
0
.0
0
1
D
u
ra
ti
o
n
,
yr
s
0
.0
6
9
(0
.0
1
1
)
,
0
.0
0
0
1
C
o
m
o
rb
id
d
is
e
as
e
{
0
.7
1
7
(0
.2
3
4
)
0
.0
0
3
St
e
ro
id
u
se
1
.0
9
0
(0
.3
2
3
)
0
.0
0
1
1
D
u
ra
ti
o
n
,
yr
s
0
.0
1
7
(0
.0
0
6
8
)
0
.0
0
5
C
ar
st
ai
rs
in
d
e
x
0
.0
5
6
(0
.0
2
2
)
0
.0
1
1
St
e
ro
id
u
se
0
.4
1
4
(0
.2
0
1
)
0
.0
4
2
M
T
A
:
m
e
an
-t
im
e
-a
ve
ra
g
e
d
va
lu
e
s
o
ve
r
2
4
m
o
n
th
s,
sc
o
re
d
at
b
as
e
lin
e
,
1
2
an
d
2
4
m
o
n
th
s.
B
as
e
d
o
n
1
0
3
(7
6
.9
%
)
m
al
e
p
at
ie
n
ts
w
h
o
h
ad
b
e
e
n
fo
llo
w
e
d
u
p
fo
r
2
4
m
o
n
th
s
w
it
h
m
e
as
u
re
m
e
n
ts
at
e
ac
h
ti
m
e
p
o
in
t
av
ai
la
b
le
.
In
d
e
p
e
n
d
e
n
t
va
ri
ab
le
s
w
e
re
b
as
e
lin
e
va
lu
e
s.
*M
T
A
-M
JS
w
as
sq
u
ar
e
ro
o
t
tr
an
sf
o
rm
e
d
to
fi
t
n
o
rm
al
it
y.
,
{ P
re
se
n
ce
o
f
an
y
co
m
o
rb
id
d
is
e
as
e
(e
.g
is
ch
ae
m
ic
h
e
ar
t
d
is
e
as
e
,
d
ia
b
e
te
s,
ch
ro
n
ic
p
u
lm
o
n
ar
y
d
is
e
as
e
,
re
n
al
d
is
e
as
e
,
n
e
o
p
la
si
a)
.
R
-s
q
u
ar
e
d
va
lu
e
s:
M
o
d
e
l
1
=
0
.2
3
2
7
,
M
o
d
e
l
2
=
0
.3
9
6
7
,
M
o
d
e
l
3
=
0
.3
0
5
8
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
6
4
8
6
2
.t
0
0
5
Body Height and Rheumatoid Arthritis
PLOS ONE | www.plosone.org 6 May 2013 | Volume 8 | Issue 5 | e64862
T
a
b
le
6
.
M
u
lt
iv
ar
ia
te
m
u
lt
ip
le
re
g
re
ss
io
n
an
al
ys
e
s
sh
o
w
in
g
b
as
e
lin
e
va
ri
ab
le
s
m
o
st
st
ro
n
g
ly
as
so
ci
at
e
d
w
it
h
D
A
S2
8
,M
JS
an
d
H
A
Q
sc
o
re
o
ve
r
ti
m
e
(2
4
m
o
n
th
s)
in
fe
m
al
e
p
at
ie
n
ts
w
it
h
R
A
.
M
o
d
e
l
1
,
d
e
p
e
n
d
e
n
t
v
a
ri
a
b
le
:
M
T
A
-D
A
S
2
8
M
o
d
e
l
2
,
d
e
p
e
n
d
e
n
t
v
a
ri
a
b
le
:
M
T
A
-M
JS
*
M
o
d
e
l
3
,
d
e
p
e
n
d
e
n
t
v
a
ri
a
b
le
:
M
T
A
-H
A
Q
In
d
e
p
e
n
d
e
n
t
v
a
ri
a
b
le
R
e
g
re
ss
io
n
co
e
ff
ic
ie
n
t
(S
E
)
p
v
a
lu
e
In
d
e
p
e
n
d
e
n
t
v
a
ri
a
b
le
R
e
g
re
ss
io
n
co
e
ff
ic
ie
n
t
(S
E
)
p
v
a
lu
e
In
d
e
p
e
n
d
e
n
t
v
a
ri
a
b
le
R
e
g
re
ss
io
n
co
e
ff
ic
ie
n
t
(S
E
)
p
v
a
lu
e
R
F
(+
/2
)
0
.0
1
8
(0
.0
0
7
)
0
.0
0
3
6
D
u
ra
ti
o
n
,
yr
s
0
.0
9
3
(0
.0
0
8
6
)
,
0
.0
0
0
1
D
u
ra
ti
o
n
,
yr
s
0
.0
2
5
(0
.0
0
4
7
)
,
0
.0
0
0
1
B
M
I
0
.0
3
8
(0
.0
1
4
)
0
.0
0
8
8
R
F
(+
/2
)
0
.4
3
5
(0
.1
6
0
)
0
.0
0
7
ES
R
,
m
m
/h
0
.0
0
9
(0
.0
0
2
)
0
.0
0
0
2
A
g
e
,
yr
s
0
.0
1
8
(0
.0
0
7
6
)
0
.0
2
0
C
ar
st
ai
rs
in
d
e
x
0
.0
4
5
(0
.0
1
8
)
0
.0
1
2
C
o
m
o
rb
id
d
is
e
as
e
{
0
.4
3
7
(0
.2
1
5
)
0
.0
4
4
H
ip
re
p
la
ce
m
e
n
t
0
.3
5
0
(0
.1
5
9
)
0
.0
3
3
M
T
A
:
m
e
an
-t
im
e
-a
ve
ra
g
e
d
va
lu
e
s
o
ve
r
2
4
m
o
n
th
s,
sc
o
re
d
at
b
as
e
lin
e
,
1
2
an
d
2
4
m
o
n
th
s.
B
as
e
d
o
n
2
0
2
(7
0
.4
%
)
fe
m
al
e
p
at
ie
n
ts
w
h
o
h
ad
b
e
e
n
fo
llo
w
e
d
u
p
fo
r
2
4
m
o
n
th
s
w
it
h
m
e
as
u
re
m
e
n
ts
at
e
ac
h
ti
m
e
p
o
in
t
av
ai
la
b
le
.
In
d
e
p
e
n
d
e
n
t
va
ri
ab
le
s
w
e
re
b
as
e
lin
e
va
lu
e
s.
*M
T
A
-M
JS
w
as
sq
u
ar
e
ro
o
t
tr
an
sf
o
rm
e
d
to
fi
t
n
o
rm
al
it
y.
{ P
re
se
n
ce
o
f
an
y
co
m
o
rb
id
d
is
e
as
e
(e
.g
is
ch
ae
m
ic
h
e
ar
t
d
is
e
as
e
,
d
ia
b
e
te
s,
ch
ro
n
ic
p
u
lm
o
n
ar
y
d
is
e
as
e
,
re
n
al
d
is
e
as
e
,
n
e
o
p
la
si
a)
.
R
F,
rh
e
u
m
at
o
id
fa
ct
o
r;
B
M
I,
b
o
d
y
m
as
s
in
d
e
x;
ES
R
,
e
ry
th
ro
cy
te
se
d
im
e
n
ta
ti
o
n
ra
te
.
R
-s
q
u
ar
e
d
va
lu
e
s:
M
o
d
e
l
1
=
0
.1
4
6
4
,
M
o
d
e
l
2
=
0
.4
0
5
6
,
M
o
d
e
l
3
=
0
.2
3
5
8
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
6
4
8
6
2
.t
0
0
6
T
a
b
le
7
.
M
u
lt
iv
ar
ia
te
m
u
lt
ip
le
re
g
re
ss
io
n
an
al
ys
e
s
sh
o
w
in
g
va
ri
ab
le
s
m
o
st
st
ro
n
g
ly
as
so
ci
at
e
d
w
it
h
D
A
S2
8
,
M
JS
an
d
H
A
Q
sc
o
re
in
al
l
p
at
ie
n
ts
w
it
h
R
A
(a
d
ju
st
e
d
fo
r
g
e
n
d
e
r)
.
M
o
d
e
l
1
,
d
e
p
e
n
d
e
n
t
v
a
ri
a
b
le
:
D
A
S
2
8
M
o
d
e
l
2
,
d
e
p
e
n
d
e
n
t
v
a
ri
a
b
le
:
M
JS
*
M
o
d
e
l
3
,
d
e
p
e
n
d
e
n
t
v
a
ri
a
b
le
:
H
A
Q
In
d
e
p
e
n
d
e
n
t
v
a
ri
a
b
le
R
e
g
re
ss
io
n
co
e
ff
ic
ie
n
t
(S
E
)
p
v
a
lu
e
In
d
e
p
e
n
d
e
n
t
v
a
ri
a
b
le
R
e
g
re
ss
io
n
co
e
ff
ic
ie
n
t
(S
E
)
p
v
a
lu
e
In
d
e
p
e
n
d
e
n
t
v
a
ri
a
b
le
R
e
g
re
ss
io
n
co
e
ff
ic
ie
n
t
(S
E
)
p
v
a
lu
e
H
e
ig
h
t,
cm
2
0
.0
2
2
2
(0
.0
0
9
)
0
.0
2
3
H
e
ig
h
t,
cm
2
0
.0
1
4
2
(0
.0
0
7
)
0
.0
2
9
H
e
ig
h
t,
cm
2
0
.0
1
2
2
(0
.0
0
3
)
0
.0
1
9
R
F
(+
/2
)
0
.6
0
5
(0
.1
3
0
)
,
0
.0
0
0
1
D
u
ra
ti
o
n
,
yr
s
0
.0
8
5
(0
.0
0
6
)
,
0
.0
0
0
1
D
u
ra
ti
o
n
,
yr
s
0
.0
2
1
(0
.0
0
3
)
,
0
.0
0
0
1
C
o
m
o
rb
id
d
is
e
as
e
{
0
.8
4
1
(0
.1
9
0
)
,
0
.0
0
0
1
O
st
e
o
p
o
ro
si
s
0
.7
6
9
(0
.1
8
3
)
,
0
.0
0
0
1
ES
R
,
m
m
/h
0
.0
0
8
(0
.0
0
2
)
,
0
.0
0
0
1
St
e
ro
id
u
se
0
.5
0
0
(0
.2
1
6
)
0
.0
2
1
C
R
P
,
m
g
/l
0
.0
0
8
4
(0
.0
0
2
6
)
0
.0
0
2
C
ar
st
ai
rs
in
d
e
x
0
.0
5
9
(0
.0
1
3
)
,
0
.0
0
0
1
Fe
m
al
e
2
0
.0
1
4
5
(0
.1
8
9
)
0
.9
3
R
F
(+
/2
)
0
.2
9
5
(0
.1
2
6
)
0
.0
2
0
C
o
m
o
rb
id
d
is
e
as
e
{
0
.3
1
8
(0
.0
9
8
)
0
.0
0
1
Fe
m
al
e
2
0
.1
9
0
(0
.1
8
2
)
0
.3
0
St
e
ro
id
u
se
0
.3
0
8
(0
.1
1
4
)
0
.0
0
7
H
ip
re
p
la
ce
m
e
n
t
0
.2
3
4
(0
.1
1
7
)
0
.0
4
8
Fe
m
al
e
0
.0
4
8
(0
.0
9
8
)
0
.6
2
V
ar
ia
b
le
s
w
e
re
b
as
e
lin
e
va
lu
e
s.
*M
JS
w
as
sq
u
ar
e
ro
o
t
tr
an
sf
o
rm
e
d
to
fi
t
n
o
rm
al
it
y,
{ P
re
se
n
ce
o
f
an
y
co
m
o
rb
id
d
is
e
as
e
(e
.g
is
ch
ae
m
ic
h
e
ar
t
d
is
e
as
e
,
d
ia
b
e
te
s,
ch
ro
n
ic
p
u
lm
o
n
ar
y
d
is
e
as
e
,
re
n
al
d
is
e
as
e
,
n
e
o
p
la
si
a)
.
R
F,
rh
e
u
m
at
o
id
fa
ct
o
r;
C
R
P
,
C
-r
e
ac
ti
ve
p
ro
te
in
;
ES
R
,
e
ry
th
ro
cy
te
se
d
im
e
n
ta
ti
o
n
ra
te
.
M
o
d
e
ls
sh
o
w
n
ad
ju
st
e
d
fo
r
g
e
n
d
e
r.
In
m
o
d
e
ls
u
n
ad
ju
st
e
d
fo
r
g
e
n
d
e
r
th
e
as
so
ci
at
io
n
s
w
it
h
h
e
ig
h
t
re
m
ai
n
e
d
si
g
n
if
ic
an
t
(D
A
S2
8
,
p
=
0
.0
0
2
;
M
JS
,
p
=
0
.0
4
3
,
H
A
Q
,
p
=
0
.0
0
0
2
).
R
-s
q
u
ar
e
d
va
lu
e
s:
M
o
d
e
l
1
=
0
.1
3
5
9
,
M
o
d
e
l
2
=
0
.3
8
3
3
,
M
o
d
e
l
3
=
0
.2
7
9
2
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
6
4
8
6
2
.t
0
0
7
Body Height and Rheumatoid Arthritis
PLOS ONE | www.plosone.org 7 May 2013 | Volume 8 | Issue 5 | e64862
with a higher DAS28 and HAQ score in models adjusted for other
significant variables. No association was seen with MJS (Table S4).
Replication study
Replication of these analyses in a second population of RA
patients provided confirmation of the influence of height on
disease activity and function. In all patients there was a significant
inverse correlation of height with DAS28 (20.174, p = 0.0030) and
HAQ (20.346, p = 0.0006). The DAS28 and HAQ were again
significantly higher in females than males (5.0 v 4.59, p = 0.016
and 1.65 v 1.19, p = 0.0050), but these associations were lost after
adjusting for height in multiple regression models (data not
shown). The mediation effect also reached significance in this
smaller dataset for HAQ (a6b effect: 0.261 (0.074–0.506)).
We also examined subgroups of male and female patients who
were either height matched (median 168 cm), or were disparate in
height (female median 153 cm, male median 178 cm). Multiple
regression analysis on height matched patients showed that gender
was not associated with DAS28 (p = 0.20) or HAQ (p = 0.70) in
models containing age, disease duration and body weight (or BMI)
as independent variables. However, in the subgroup with disparate
height, female sex was associated with a higher DAS28 (p = 0.030)
and HAQ score (p = 0.0004) in models adjusted for age, disease
duration and body weight (or BMI).
Discussion
This study has demonstrated for the first time that the normal
variation of adult height is strongly associated with major disease
characteristics in RA. Furthermore, the association of female sex
with more active RA and worse function is lost after adjustment
for height, suggesting that this relationship may be due to the
smaller stature of females. Analysis of the mediation effect showed
that height may serve as a full mediator in the relationship of
gender with disease activity and overall disability in RA. In gender
specific analysis, short stature in male patients was significantly
associated with worse disease activity, impairment of mechanical
joint function and disability, whilst in females, the relationship was
weaker with a significant correlation being found only with
disability. However the latter association disappeared when
adjusted for other variables associated with the HAQ score.
Different gender specific associations are common in RA, with
females often reported as having higher levels of disease activity
and worse functional outcome [20–25], while males have greater
autoantibody production [26]. Higher DAS/DAS28 scores in
women have been reported in early disease (,12 months) in some
[21,25], but not all studies [20,24], but consistently higher female
DAS28 scores have been observed in early RA patients followed
up prospectively for 5 years [25], and in cross sectional studies of
longstanding RA [21,22]. Higher HAQ scores in women have
invariably been found patients with early and established disease
[20–25]. It has been suggested that higher DAS28 and HAQ in
women is possibly due to higher pain perception and less muscular
strength. However we did not find a significant difference in pain
scores between men and women in this group (unpublished
observations). Also, it does not explain why height matched men
and women had similar HAQ scores, since we would still have
expected the men to have greater muscular strength than the
women. Another suggestion is that the menopausal state is
responsible for a major part of the differences in outcome between
men and women, with postmenopausal women having worse
disability and damage [20]. However, we have found that
although postmenopausal women have significantly higher
DAS28 and HAQ scores than men and premenopausal women,
these associations disappear when adjusted for height (unpublished
observations).
Further evidence for the influence of height was provided by
sub-group analysis which showed no differences in gender for
disease activity or functional outcome after matching for height.
Differences in height are associated with differences in bone
geometry, limb proportions, joint angles, etc. Although height is
largely affected by gender, these differences, rather than other sex-
related factors (e.g. sex hormones), may be more influential in
affecting joint damage.
Body height is likely to be marker for some other environmental
or biological process rather than be a causal factor itself. Potential
factors influencing height include socio-economic status, smoking,
in utero maternal health, nutritional status in childhood and early-
life infections. In this study adjustment for the Carstairs
deprivation index and smoking history made no difference to the
associations with height, but no information was available on
childhood infections or nutrition in this cohort. Increased burden
of infection, immunity and inflammation in children/teenagers
have an adverse impact on linear growth and pubertal develop-
ment, and hence adult height [8,12]. Early-onset chronic
autoimmune/inflammatory diseases, such as type I diabetes, celiac
disease and paediatric inflammatory bowel disease (particularly
Crohn’s disease), are associated with growth impairment in
children/teenagers, although other factors contribute, including
nutritional deficit and/or abnormality of the growth hormone/
insulin-like growth factor 1 (GH/IGF-1) axis [27–29].
Growth hormone (GH) is fundamental to linear growth, and
primarily acts as a promoter of skeletal long bone growth/
development and chondrocyte maturation [30]. GH stimulates
insulin-like growth factor 1 (IGF-1) synthesis, and the latter is
responsible for stimulating cartilage and bone extracellular matrix
protein synthesis [30]. Deficiency in these proteins thus results in
growth retardation, short adult stature, low bone mineral density
Figure 1. Mediation model for height as a mediator in the relationship between gender and disease measures in RA. Gender,
independent variable; body height, mediator variable; disease activity and outcome in RA, dependent variable. Path of effect: a, effect of independent
variable on mediator variable; b, effect of mediator variable on dependent variable; c, total effect of independent variable on dependent variable;
a6b, indirect effect of independent variable on dependent variable; c’, direct effect of independent variable on dependent variable; c = c’+a6b.
doi:10.1371/journal.pone.0064862.g001
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and bone mass. This would be likely to increase the risk of more
severe erosive damage in patients with RA. Recently, a possible
association of GH deficiency with autoimmunity and inflamma-
tion was suggested [31,32]. Furthermore, low levels of IGF-1 in
RA synovial fluid were found to be associated with systemic
inflammation [33]. It is noteworthy that in genome wide
association studies (GWAS) a genetic variant in the IFG1 gene
was found to be associated with adult height in eastern Asian
populations (but not in Caucasians) [34,35].
It has been proposed that early-life infections may impose a life-
long inflammatory burden which may lead to the development of
atherosclerotic and thrombotic conditions in late-life [12]. This
model also links maternal infections and inflammation with fetal
and infant inflammation and reduced growth. In line with this
argument, short stature has been associated with increased risk for
CVD, type II diabetes and periodontitis [6–8]. Interestingly, RA
shows numerous characteristics and pathogenetic processes that
have similarities to periodontitis [36]. We speculate that this
pathophysiological model may provide some explanation for our
observation that short stature is associated with more severe RA.
Another important consideration is the effect of the large
number of genetic variants which underlie growth/development,
and hence adult height. Based on recent large-scale genome-wide
association studies (GWAS), a single-nucleotide polymorphism
(SNP) in the CDK6 gene, a key controller of cell cycle progression,
was found to be associated with both adult height and the
susceptibility to RA [37,38]. GWAS also identified a SNP in the
GDF5 gene which is strongly associated both with low adult height
and susceptibility to osteoarthritis (OA) [39–41]. GDF5 is a
member of the TGF-beta superfamily, and is involved in bone
growth and differentiation and joint development, both in adult
and embryonic tissues [42–45]. Rare mutations in the GDF5 gene
have been associated with several disorders of skeletal develop-
ment [39]. The allele, associated with decrease in stature/
susceptibility to OA, has been shown to be associated with
decreased GDF5 transcriptional activity in chondrogenic cells and
with in vivo reduced expression of GDF5 in articular cartilage
[39,40]. GDF5 may play a role in repair of damaged joint tissues
(e.g. cartilage), and decrease in GDF5 expression may lead to less
regeneration.
Other possible genetic candidates include the ESR1 gene which
is associated with both adult height and age at onset of RA [2,46],
and several genes implicated in both the extracellular matrix
pathway and adult height, including MMP24, ECM2, EFEMP1,
ADAMTS13 and ACAN [2,36,47]. Further work on the
relationship between genetic variants, height and disease severity
in RA may provide novel insights into the understanding of the
aetiology/pathology of the disease.
There are some limitations to this study due to its cross-sectional
nature. Analysis of the relationship between height and disease
measures is complicated by secular trends in adult height over
recent generations in which there is increased height in younger
generations [48]. Furthermore the height in older generations may
be reduced due to age related reduction in intervertebral disc
height or a loss of vertebral height from osteoporotic vertebral
collapse. Adult height also decreases with general ill health and
immobility, so the possibility of established, severe RA leading to a
greater reduction in height (reverse causation) is a major
consideration. However, we found that the inverse association of
height with greater disease activity/severity in men remained
significant in models adjusted for age, disease duration, osteopo-
rosis, comorbid disease or the presence of other autoimmune
conditions. Moreover, other possible confounders such as steroid
use, erosive disease, joint replacement, extra-articular disease,
presence of autoantibodies and socio-economic status had no
significant effect on the relationship between height and disease
activity/severity. However, it is clear from the R-squared values in
our models that a large amount of the variance in the dependent
variables is unexplained by the variables in each of the models.
Other unknown/untested factors are therefore important. We
were unable to investigate some associations, such as the reported
relationship between low serum 25-hydroxyvitamin D (25(OH)D)
levels and decreased height [49]. A possible relationship of
25(OH)D deficiency with more severe disease activity in RA [50]
suggests that this variable should be considered in future studies on
body height and severity of disease.
Further prospective studies of recent onset RA and studies in
larger cohorts are needed to confirm our findings. Future studies
should also include measurement of leg length since the effects of
age and disease severity are likely to have less effect on this
component of adult height.
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